Pharmacogenetics of the human beta-adrenergic receptors
暂无分享,去创建一个
[1] M. Wjst,et al. Association of beta(2)-adrenoreceptor variants with bronchial hyperresponsiveness. , 2000, American journal of respiratory and critical care medicine.
[2] H. Kroemer,et al. Pharmacogenomics of heart failure -- focus on drug disposition and action. , 2004, Cardiovascular research.
[3] T. Ogihara,et al. Trp64Arg mutation of beta3-adrenergic receptor in essential hypertension: insulin resistance and the adrenergic system. , 1997, American journal of hypertension.
[4] E. Silverman,et al. Beta 2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. , 2004, Chest.
[5] E. Boerwinkle,et al. β2 adrenergic receptor 5′ haplotypes influence promoter activity , 2002, British journal of pharmacology.
[6] J. Granneman,et al. Rodent and human beta 3-adrenergic receptor genes contain an intron within the protein-coding block. , 1992, Molecular pharmacology.
[7] P R Burton,et al. Gibbs sampling–based segregation analysis of asthma‐associated quantitative traits in a population‐based sample of nuclear families , 2001, Genetic epidemiology.
[8] R. Hetzer,et al. Regional distribution of beta-adrenoceptors in the human heart: coexistence of functional beta 1- and beta 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. , 1986, Journal of cardiovascular pharmacology.
[9] M. Bristow. Changes in myocardial and vascular receptors in heart failure. , 1993, Journal of the American College of Cardiology.
[10] S. Ball,et al. Common polymorphisms of β1-adrenoceptor: identification and rapid screening assay , 1999, The Lancet.
[11] W. Cookson,et al. Genomic approaches to understanding asthma. , 2000, Genome research.
[12] J. Lélias,et al. Molecular cloning of a human beta 3-adrenergic receptor cDNA. , 1993, FEBS letters.
[13] S. Liggett. Pharmacogenetics of Beta-1- and Beta-2-Adrenergic Receptors , 2000, Pharmacology.
[14] L. Tiret,et al. Characterization of a Unique Genetic Variant in the β1-adrenoceptor Gene and Evaluation of its Role in Idiopathic Dilated Cardiomyopathy , 1999 .
[15] E. Israel,et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.
[16] Xiping Xu,et al. Ascaris lumbricoides infection is associated with increased risk of childhood asthma and atopy in rural China. , 2002, American journal of respiratory and critical care medicine.
[17] S. Liggett. β2-Adrenergic Receptor Pharmacogenetics , 2000 .
[18] R. Olshen,et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. , 2002, American journal of human genetics.
[19] Physiological significance of beta-adrenergic receptor polymorphisms: in-vivo or in-vitro veritas? , 2001, Pharmacogenetics.
[20] Matthias Wjst,et al. Association of β2-Adrenoreceptor Variants with Bronchial Hyperresponsiveness , 2000 .
[21] P. Eriksson,et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. , 1997, The Journal of clinical investigation.
[22] K. Michaëlsson,et al. Beta1‐adrenergic receptor gene polymorphisms and response to Beta1‐adrenergic receptor blockade in patients with essential hypertension , 2004, Clinical cardiology.
[23] A. Wood. Variability in beta-adrenergic receptor response in the vasculature: Role of receptor polymorphism. , 2002, The Journal of allergy and clinical immunology.
[24] G. Jennings,et al. Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. , 2003, Pharmacogenetics.
[25] J. Callés-Escandon,et al. Insulin resistance and type 2 diabetes mellitus: its relationship with the beta 3-adrenergic receptor. , 1999, Archives of medical research.
[26] E. Boerwinkle,et al. Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension. , 2000, Circulation.
[27] B. Lejeune,et al. Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia. , 2001, The American journal of cardiology.
[28] R S Judson,et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Mobini,et al. Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. , 2005, Clinical pharmacology and therapeutics.
[30] M. Böhm,et al. The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. , 2004, Pharmacogenetics.
[31] G. Jennings,et al. Adrenergic nervous system in heart failure. , 1997, The American journal of cardiology.
[32] M. Börjesson,et al. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. , 2000, European heart journal.
[33] S. Jamieson,et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.
[34] S. Liggett,et al. Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. , 1998, The Journal of clinical investigation.
[35] J. Balligand,et al. Beta3-adrenoceptors in the cardiovascular system. , 2000, Trends in pharmacological sciences.
[36] G. Dorn,et al. Polymorphisms of the β2-Adrenergic Receptor Determine Exercise Capacity in Patients With Heart Failure , 2000 .
[37] J. Haines,et al. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. , 1999, Pharmacogenetics.
[38] D C Harrison,et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.
[39] Julie A. Johnson,et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. , 2005, Pharmacogenetics and genomics.
[40] Matthew R. G. Taylor,et al. The emerging pharmacogenomics of the beta-adrenergic receptors. , 2004, Congestive heart failure.
[41] J. Port,et al. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. , 2001, Journal of molecular and cellular cardiology.
[42] C. Bogardus,et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. , 1995, The New England journal of medicine.
[43] D. A. Mason,et al. Racial differences in the frequencies of cardiac β1‐adrenergic receptor polymorphisms: Analysis of c145A>G and c1165G>C , 1999, Human mutation.
[44] T. McIntosh,et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. , 1998, The Journal of clinical investigation.
[45] A. Strosberg. Association of beta 3-adrenoceptor polymorphism with obesity and diabetes: current status. , 1997, Trends in pharmacological sciences.
[46] A. Strosberg,et al. The promoter and intron/exon structure of the human and mouse beta 3-adrenergic-receptor genes. , 1993, European journal of biochemistry.
[47] S. Green,et al. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.
[48] P. Arner,et al. Adrenoceptor genes in human obesity , 1999, Journal of internal medicine.
[49] J. Callés-Escandon,et al. Insulin Resistance and Type 2 Diabetes Mellitus , 1999 .
[50] R. Mobini,et al. Ser49Gly of β1‐adrenergic receptor is associated with effective β‐blocker dose in dilated cardiomyopathy , 2005 .
[51] M. Esler,et al. Interaction between cardiac sympathetic drive and heart rate in heart failure: modulation by adrenergic receptor genotype. , 2004, Journal of the American College of Cardiology.
[52] D. Langin,et al. Regulation of beta3‐adrenoceptor expression in white fat cells * , 1995, Fundamental & clinical pharmacology.
[53] Pharmacogenomics in hypertension: present practicalities and future potential. , 2005, Journal of hypertension.
[54] A. Strosberg,et al. The human β3-adrenoceptor: the search for a physiological function , 1994 .
[55] S. Kardia,et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. , 2002, The New England journal of medicine.
[56] H. Bruck,et al. Beta-adrenoceptor polymorphisms. , 2004, Naunyn-Schmiedeberg's archives of pharmacology.
[57] M. Heo,et al. Meta-analysis of the association of the Trp64Arg polymorphism in the β3 adrenergic receptor with body mass index , 1998, International Journal of Obesity.
[58] A. Strosberg,et al. The human beta 3-adrenoceptor: the search for a physiological function. , 1994, Trends in pharmacological sciences.
[59] Gutiérrez,et al. β3‐adrenoreceptor gene polymorphism and leptin. Lack of relationship in type 2 diabetic patients , 1998 .
[60] R. Kim,et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. , 2001, The New England journal of medicine.
[61] J. Chambers,et al. The tissue distribution of the human β3-adrenoceptor studied using a monoclonal antibody: Direct evidence of the β3-adrenoceptor in human adipose tissue, atrium and skeletal muscle , 1999, International Journal of Obesity.
[62] L. Palmer,et al. Pharmacogenetics of asthma. , 2002, American journal of respiratory and critical care medicine.
[63] S. Marullo,et al. The Myocardium-protective Gly-49 Variant of the β1-Adrenergic Receptor Exhibits Constitutive Activity and Increased Desensitization and Down-regulation* , 2002, The Journal of Biological Chemistry.
[64] S. Liggett,et al. Amino Acid 49 Polymorphisms of the Human &bgr; 1 -Adrenergic Receptor Affect Agonist-Promoted Trafficking , 2002, Journal of cardiovascular pharmacology.
[65] G. Dorn,et al. β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure , 2003, Nature Medicine.
[66] S. Kardia,et al. Synergistic Polymorphisms of β1- and α2C-Adrenergic Receptors and the Risk of Congestive Heart Failure , 2002 .
[67] R. Fagard,et al. The CAREGENE study: polymorphisms of the beta1-adrenoceptor gene and aerobic power in coronary artery disease. , 2006, European heart journal.
[68] K. Silver,et al. Pancreatic beta-cells expressing the Arg64 variant of the beta(3)-adrenergic receptor exhibit abnormal insulin secretory activity. , 2001, Journal of molecular endocrinology.
[69] D. Postma,et al. Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytes. , 2005, American journal of respiratory and critical care medicine.
[70] S. Liggett. beta(2)-adrenergic receptor pharmacogenetics. , 2000, American journal of respiratory and critical care medicine.
[71] K. Adams,et al. β‐adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure , 2005, Clinical pharmacology and therapeutics.
[72] P. Insel,et al. β2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease , 2002 .
[73] L. Groop,et al. Beta(2)-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. , 2001, Hypertension.
[74] G. Dorn,et al. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. , 2000, Circulation research.
[75] D. A. Mason,et al. A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor* , 1999, The Journal of Biological Chemistry.
[76] Jinny Park,et al. Human β2‐adrenergic receptor gene haplotypes and venodilation in vivo , 2005, Clinical pharmacology and therapeutics.
[77] B. Lowell,et al. βAR Signaling Required for Diet-Induced Thermogenesis and Obesity Resistance , 2002, Science.
[78] V. Fuster. Hurst's the Heart , 1966 .
[79] Julie A. Johnson,et al. β-Adrenergic Receptor Polymorphisms: Cardiovascular Disease Associations and Pharmacogenetics , 2002, Pharmaceutical Research.
[80] J. Lélias,et al. Molecular cloning of a human β3‐adrenergic receptor cDNA , 1993 .
[81] W. Busse,et al. Future research directions in asthma: an NHLBI Working Group report. , 2004, American journal of respiratory and critical care medicine.
[82] Matthew R. G. Taylor,et al. The Emerging Pharmacogenomics of the β-Adrenergic Receptors , 2004 .
[83] J. Balligand,et al. Upregulation of &bgr;3-Adrenoceptors and Altered Contractile Response to Inotropic Amines in Human Failing Myocardium , 2001, Circulation.
[84] S. Liggett,et al. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. , 1993, American journal of respiratory cell and molecular biology.
[85] C. Stein,et al. Pharmacogenetics and Response to β‐adrenergic Receptor Antagonists in Heart Failure , 2005, Clinical pharmacology and therapeutics.
[86] A. Strosberg. Association of β3-adrenoceptor polymorphism with obesity and diabetes: current status , 1997 .
[87] C. Bouchard,et al. Polymorphisms of the β2‐adrenergic receptor gene (ADRB2) in relation to cardiovascular risk factors in men , 2000, Journal of internal medicine.
[88] J. Ioannidis,et al. Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. , 2005, The Journal of allergy and clinical immunology.
[89] Morris J. Brown,et al. Functional responses of human beta1 adrenoceptors with defined haplotypes for the common 389R>G and 49S>G polymorphisms. , 2004, Pharmacogenetics.
[90] P. Burton,et al. Familial aggregation and heritability of asthma-associated quantitative traits in a population-based sample of nuclear families , 2000, European Journal of Human Genetics.
[91] M. Michaelson,et al. The Pharmacologic Approach to the Treatment of Obesity , 1997, Journal of clinical pharmacology.
[92] S. Green,et al. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[93] H. Bourne,et al. The expanding spectrum of G protein diseases. , 1999, The New England journal of medicine.
[94] L. Groop,et al. Polymorphism in the &bgr;1-Adrenergic Receptor Gene and Hypertension , 2001, Circulation.
[95] M. Heo,et al. Meta-analysis of the association of the Trp64Arg polymorphism in the beta3 adrenergic receptor with body mass index. , 1998, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[96] M. Maioli,et al. Association of Trp64Arg beta 3-adrenergic-receptor gene polymorphism with essential hypertension in the Sardinian population. , 1999, Journal of hypertension.
[97] D. Herrington,et al. Pharmacogenomics of blood pressure response to antihypertensive treatment , 2005, Journal of hypertension.
[98] H. Bruck,et al. β-Adrenoceptor polymorphisms , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.
[99] R. Erickson,et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. , 1997, The Journal of clinical investigation.
[100] A. Koyanagi,et al. Polymorphism in the 5'-leader cistron of the beta2-adrenergic receptor gene associated with obesity and type 2 diabetes. , 1999, The Journal of clinical endocrinology and metabolism.
[101] S. Green,et al. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. , 1994, Biochemistry.
[102] B. Kobilka,et al. The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis. , 1994, The Journal of biological chemistry.
[103] A. Evans,et al. Polymorphisms of the β2-adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies , 2002, Journal of hypertension.
[104] F. Leonetti,et al. Association of β2 adrenergic receptor polymorphisms and related haplotypes with triglyceride and LDL-cholesterol levels , 2006, European Journal of Human Genetics.
[105] L. Tiret,et al. Characterization of a unique genetic variant in the beta1-adrenoceptor gene and evaluation of its role in idiopathic dilated cardiomyopathy. CARDIGENE Group. , 1999, Journal of molecular and cellular cardiology.
[106] R. Hetzer,et al. Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? , 2000, Journal of molecular medicine.
[107] M. Austin,et al. Trp64Arg polymorphism of the β3-adrenergic receptor gene, pre-pregnancy obesity and risk of pre-eclampsia , 2005, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[108] N. Cook,et al. Haplotype Analysis of the β2 Adrenergic Receptor Gene and Risk of Myocardial Infarction in Humans , 2005, Genetics.
[109] Marsha Wills-Karp,et al. Time to draw breath: asthma-susceptibility genes are identified , 2004, Nature Reviews Genetics.
[110] P. Insel,et al. beta2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. , 2002, Pharmacogenetics.
[111] J. Balligand,et al. The negative inotropic action of catecholamines: role of beta3-adrenoceptors. , 2000, Canadian journal of physiology and pharmacology.